Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25013562 | 0.90 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL25909400 | 0.88 | TMPRSS2 (0.47) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL25608083 | 0.88 | TMPRSS2 (0.41) | TMPRSS2POLRMT | |
| SCHEMBL20144199 | 0.86 | POLRMT (0.33) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL18666902 | 0.86 | POLRMT (0.33) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL18636477 | 0.85 | TMPRSS2 (0.45) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL25381965 | 0.85 | TMPRSS2 (0.47) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL15580646 | 0.85 | PRMT5 (0.34) | TMPRSS2TNK2PRMT5WDR77 | |
| SCHEMBL24407360 | 0.84 | TMPRSS2 (0.46) | TMPRSS2POLRMT | |
| SCHEMBL17722662 | 0.83 | TMPRSS2 (0.45) | TMPRSS2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2021-07-29 | — | — | US | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | MTAP, SARS1, PNP | TMPRSS2 100/4885POLRMT 34/4885TNK2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.